IIM
ACRS icon

INTECH Investment Management’s Aclaris Therapeutics ACRS Stock Holding History

INTECH Investment Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$72K Sell
19,196
-27,450
-59% -$92.6K ﹤0.01% 1957
2025
Q4 		$140K Buy
46,646
+7,702
+20% +$19.5K ﹤0.01% 2090
2025
Q3 		$74K Sell
38,944
-5,787
-13% -$10.1K ﹤0.01% 2324
2025
Q2 		$63.5K Buy
+44,731
New +$60.5K ﹤0.01% 2389

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

INTECH Investment Management's ACRS Position: Q1 2026 in Review

INTECH Investment Management reduced its Aclaris Therapeutics (ACRS) stake by 59% in Q1 2026, selling an estimated $92.6K and leaving 19,196 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #1957.

INTECH Investment Management first reported a position in ACRS in Q2 2025 and has held it in 4 quarters since. The position peaked at $140K in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • INTECH Investment Management held 19,196 shares of Aclaris Therapeutics worth $72K as of Q1 2026.
  • INTECH Investment Management sold 27,450 Aclaris Therapeutics shares in Q1 2026, an estimated $92.6K.
  • Aclaris Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q1 2026, its #1957 holding.
  • INTECH Investment Management first reported a position in Aclaris Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • INTECH Investment Management's Aclaris Therapeutics position peaked at $140K in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on INTECH Investment Management's 13F filing for Q1 2026, filed 8 May 2026.